높은 처리량, 실시간, 세포 내 항균 활동의 이중 판독 테스트 및 진핵 세포의 세포 독성

Executive Industry Relevance

High-throughput, real-time dual-readout assays for intracellular antimicrobial activity and eukaryotic cell cytotoxicity address a critical bottleneck in early anti-infective discovery. By enabling simultaneous, non-destructive measurement of compound efficacy and host cell safety, this approach increases predictive confidence and accelerates triage of candidate molecules. The method supports scalable screening and robust data generation for portfolio-level decision making in anti-infective R&D.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct interrogation of compound penetration and intracellular pathogen inhibition.
• Supports functional target validation by linking antimicrobial action to host cell viability.
• Facilitates mechanistic de-risking by distinguishing selective inhibitors from cytotoxic agents.
• Improves predictive confidence for advancing hits to lead optimization.

Screening & Assay Development

• Delivers validated, scalable assay formats for high-throughput compound evaluation.
• Provides quantitative, real-time readouts for both bacterial growth and host cytotoxicity.
• Enables reproducible, automated workflows compatible with digital dispensing robotics.
• Supports rapid dose-response and synergy testing in microplate formats.

Translational & Preclinical Research

• Aligns in vitro screening with disease-relevant intracellular infection models.
• Enables continuity from early discovery through preclinical validation for intracellular pathogens.
• Supports risk-adjusted advancement by integrating efficacy and safety data in a single assay.
• Facilitates translational biomarker development by correlating compound activity with host cell outcomes.

Pipeline & Workflow Integration

This dual-readout assay bridges early discovery and lead identification, providing a foundation for downstream preclinical evaluation of anti-infective candidates.

• Discovery Biology: Supports hypothesis testing on compound selectivity and intracellular efficacy.
• Screening: Delivers high-throughput, reproducible, and quantitative outputs for compound triage.
• Analytics: Enables dual IC50/CC50 determination and synergy mapping for informed decision making.
• Translational Research: Connects in vitro findings to disease-relevant infection models for preclinical continuity.
• Enterprise Reuse: Provides a reusable, scalable platform adaptable to multiple intracellular pathogens and compound libraries.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in anti-infective discovery.
• Operational Value: Standardizes and automates high-throughput screening with real-time, multiplexed readouts.
• Strategic Value: Enables efficient go/no-go decisions and capital allocation by integrating efficacy and safety data.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of anti-infective candidates targeting intracellular pathogens.

Implementation Considerations

• Requires expertise in cell culture, pathogen handling, and high-throughput assay design.
• Demands access to automated liquid handling, microplate readers, and digital dispensing robotics.
• Necessitates cross-team standardization for assay setup, data analysis, and quality control.
• Adaptable to various intracellular pathogens and compatible with both luminescent and fluorescent reporters.
• Practical limitations include managing cell viability, minimizing edge effects, and ensuring uniform dispensing at scale.

Biopharma FAQs